Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botox for piriformis syndrome in active adults
NL-OMON58926Phase 4Completed
- Sponsor
- Alrijne Zorggroep
- Start
- Mar 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of botulinum toxin type A in Piriformis syndrome, sponsored by Alrijne Zorggroep. Primary endpoints: Sports resumption after BoNT-A injection and Outpatient assessment at 12 weeks after test block for withdrawn subjects. Started Mar 2024; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
Piriformis syndrome
Beyond the preview
Go deeper on NL-OMON58926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58926.